Matches in Wikidata for { <http://www.wikidata.org/entity/Q90938965> ?p ?o ?g. }
Showing items 1 to 55 of
55
with 100 items per page.
- Q90938965 description "artículu científicu espublizáu n'agostu de 2018" @default.
- Q90938965 description "scientific article published on 14 August 2018" @default.
- Q90938965 description "wetenschappelijk artikel" @default.
- Q90938965 description "наукова стаття, опублікована в серпні 2018" @default.
- Q90938965 name "First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase" @default.
- Q90938965 name "First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase" @default.
- Q90938965 type Item @default.
- Q90938965 label "First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase" @default.
- Q90938965 label "First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase" @default.
- Q90938965 prefLabel "First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase" @default.
- Q90938965 prefLabel "First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase" @default.
- Q90938965 P1433 Q90938965-4D6D73FE-072A-4A63-B6A9-29C9C01B516C @default.
- Q90938965 P1476 Q90938965-A0861F76-9C38-4237-9C9C-0A716EF4FCDA @default.
- Q90938965 P2093 Q90938965-365794D0-65F8-4405-99A0-7DC826428735 @default.
- Q90938965 P2093 Q90938965-51DCD316-209A-480A-967A-E4CE8CFC6A5A @default.
- Q90938965 P2093 Q90938965-5FBD4A48-5417-4CF4-B1B3-2FF938E52B00 @default.
- Q90938965 P2093 Q90938965-6A89BD7E-DBD6-468F-B6CD-87F3D19FC54F @default.
- Q90938965 P2093 Q90938965-6CAB91E2-53F9-43EE-90B4-5308C8DF653F @default.
- Q90938965 P2093 Q90938965-84DA798A-AFEF-4B4E-BB4C-E967ACCE41EC @default.
- Q90938965 P2093 Q90938965-9164A258-5FED-4848-97F3-9BF1B6740F2C @default.
- Q90938965 P2093 Q90938965-9ADDDB93-4989-4EE3-9018-DA492E012185 @default.
- Q90938965 P2093 Q90938965-BE45901E-9395-4BBA-9DEC-BB33679B801B @default.
- Q90938965 P2093 Q90938965-CBF1BC5E-B63A-44AC-A36D-DFA766F6A356 @default.
- Q90938965 P2093 Q90938965-DD489DFC-97F6-4CD0-99C0-C224E124E507 @default.
- Q90938965 P304 Q90938965-59A2DEE5-748A-4F4B-BCA2-F67C8A908D7A @default.
- Q90938965 P31 Q90938965-EE299658-8480-4F77-B881-AB9440703962 @default.
- Q90938965 P356 Q90938965-F4C8EE7D-36BD-4C89-8241-6CD2A53C3AFE @default.
- Q90938965 P433 Q90938965-F2AD9651-7959-4D76-99C6-573B6012878C @default.
- Q90938965 P478 Q90938965-56B20060-B331-46B6-A0A5-D2986ADFBF64 @default.
- Q90938965 P577 Q90938965-9D53794F-21DB-4409-9D3A-51EA2AB42899 @default.
- Q90938965 P698 Q90938965-4F6719EE-0066-4B22-AB4D-1AEF0CF7F3F4 @default.
- Q90938965 P921 Q90938965-92165EED-D5B1-4076-A190-8FDAA3BBED83 @default.
- Q90938965 P356 JCO.2017.76.7863 @default.
- Q90938965 P698 30106636 @default.
- Q90938965 P1433 Q400292 @default.
- Q90938965 P1476 "First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase II Trial" @default.
- Q90938965 P2093 "C Kent Osborne" @default.
- Q90938965 P2093 "Christine Wohlfarth" @default.
- Q90938965 P2093 "Christopher Poole" @default.
- Q90938965 P2093 "Grazia Arpino" @default.
- Q90938965 P2093 "Jean-Marc Ferrero" @default.
- Q90938965 P2093 "Juan de la Haba-Rodriguez" @default.
- Q90938965 P2093 "Mothaffar Rimawi" @default.
- Q90938965 P2093 "PERTAIN Study Group" @default.
- Q90938965 P2093 "Roberto Hegg" @default.
- Q90938965 P2093 "Sabino De Placido" @default.
- Q90938965 P2093 "Valerie Easton" @default.
- Q90938965 P304 "2826-2835" @default.
- Q90938965 P31 Q13442814 @default.
- Q90938965 P356 "10.1200/JCO.2017.76.7863" @default.
- Q90938965 P433 "28" @default.
- Q90938965 P478 "36" @default.
- Q90938965 P577 "2018-08-14T00:00:00Z" @default.
- Q90938965 P698 "30106636" @default.
- Q90938965 P921 Q412616 @default.